A B S T R A C T Because some nonsteroidal anti-inflammatory drugs (NSAID) induce salt and water retention and exhibit other steroid-like actions, studies were performed to ascertain whether these drugs possess intrinsic mineralocorticoid agonist activity. In vitro competitive binding assays utilizing tissue from adrenalectomized rats demonstrated that some NSAID can displace [3H]-aldosterone from renal cytoplasmic mineralocorticoid receptors. Displacement potency for these sites was in the sequence: aldosterone > spironolactone > phenylbutazone (PBZ) > aspirin (ASA) > indomethacin (IDM). Concentration ratios required to obtain significant displacement of ['H]aldosterone were high but clearly within the therapeutic range for PBZ and ASA but not IDM. The analogues oxyphenbutazone (OBZ) and sodium salicylate (SS) were similar in binding activity to PBZ and ASA, respectively. Lineweaver-Burk analysis revealed that the inhibition of [8H]aldosterone binding was competitive in nature. In addition, PBZ was shown to prevent the nuclear binding of ['H]aldosterone.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAID)1 such as aspirin (ASA), phenylbutazone (PBZ), and indomethacin (IDM) are commonly used agents whose mechanism of action is incompletely understood (1) . Recent work has suggested that the inhibition of prostaglandin synthesis plays a role in the anti-inflammatory action of these drugs (2) . However, many therapeutic effects as well as side effects of NSAID resemble responses evoked by adrenal steroids (1, 3) . A large body of evidence indicates that NSAID do not act via the pituitary-adrenal axis (1, (3) (4) (5) (6) . Although these drugs are structurally unrelated to the adrenal steroids, the available data are not inconsistent with the hypothesis that NSAID are themselves weak steroid agonists. Of interest in this respect are the findings that various NSAID, in addition to being anti-inflammatory, have been shown to elicit the following steroid-like effects: (a) retention of sodium with resultant increases in plasma volume (7) (8) (9) (10) (11) (12) , (b) suppression of lymphocyte transformation (13) , (c) antagonism of the antimineralocorticoid effects of spironolactone (11, 14, 15) , (d) occasional improvement in the condition of patients with Addison's disease (16) , and (e) suppression of the pituitary-adrenal axis (17, 18) .
In the light of these observations, it seemed appropriate to reevaluate whether NSAID could be corticosteroid agonists. Since it is currently felt that all steroid hormones initiate their action by binding to specific cytoplasmic receptors in target tissue (19) Urine was collected for 2-3 h (control period), and the animals were then injected with various drug combinations i.p. Dosages were calculated per 100 g body weight according to the following schedule: aldosterone, 1 jug; spironolactone, 2 mg; SS and ASA, 10 mg; PBZ and OBZ, 7.5 mg. The latter three drugs were dissolved in 0.2 N NaOH, titrated back to pH 7.4 with Ha, and brought to 1 ml with Tris buffer. Control rats received 1 ml of vehicle solution. The urine output over the subsequent 2 h was collected and the experimental period urine was then collected over the ensuing 3 h, (i.e., between 2 and 5 h after drug administration). Urinary sodium and potassium concentrations were determined on an Instrumentation Laboratory, Inc. (Lexington, Mass.) flame photometer, and creatinine was assayed by a modification of the Taussky method (24).
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The rats appeared to tolerate these doses of NSAID without difficulty and were reused on an alternating schedule over several weeks.
RESULTS

In vitro mineralocorticoid binding studies. NSAID,
particularly PBZ and its analogues, exhibit salt and water retention as prominent side effects (7, 8) . To determine whether this NSAID effect could be mediated by direct interaction with the mineralocorticoid receptors, competition studies were performed for [3H]aldosteronebinding sites in kidney cytosol. These experiments were performed with kidney slices in the presence of 10-fold excess unlabeled dexamethasone to block any [8H]-aldosterone binding to glucocorticoid receptors in the kidney (20, 21) . As shown in Fig. 1 , unlabeled aldosterone predictably displaced the bound [3H]aldosterone. Spironolactone, a clinically useful mineralocorticoid antagonist, displayed significant potency in these competition studies as previously reported (25) . PBZ and OBZ demonstrated approximately equivalent potency, both requiring a concentration of about 100,000-fold excess to inhibit 50% of the [3H]aldosterone binding. ASA was slightly more potent than SS, however neither achieved 50% inhibition at a 500,000-fold excess. IDM did not significantly displace any [8H]aldosterone at a concentration ratio of 10,000: 1 whereas at 100,000: (20) . In the presence of inhibitor, the plotted lines intersect at a common point on the ordinate indicating that the inhibition of binding is competitive in nature.
IcMxIo') lo Fig. 4 , aldosterone at 1 t*g/100 g resulted in significant Na' retention.
Spironolactone at 2 mg/100 g did not alter the Na' excretion but, when administered with aldosterone, inhibited most (about 85%) of the mineralocorticoid effect. PBZ and OBZ at 7.5 mg/100 g exhibited significant mineralocorticoid potency which was approximately equivalent to that elicited by aldosterone. Spironolactone also inhibited this mineralocorticoid effect. ASA and SS demonstrated minimal if any mineralocorticoid potency when compared to the changes seen in control animals. Receptor depletion studies. The effect on Na' retention elicited by a 7.5 mg/100 g dose of PBZ appeared roughly equivalent to the effect of a 1 lsg/100 g dose of aldosterone (Fig. 4 ). Yet this concentration ratio of PBZ (10,000: 1 molar ratio) achieved only -20% competition in the in vitro slice system (Fig. 1) . In an attempt to determine the actual occupancy rate of mineralocorticoid receptors attained by this dose of PBZ in vivo, the following study was performed. Aldosterone or PBZ was injected into adrenalectomized rats at the same dosage and under the same conditions as for the physiological studies. 20-30 min later the kidneys of these rats were removed and residual [8H]aldosterone cytoplasmic-binding sites measured (Table III) . Compared to control animals receiving vehicle, aldosterone depleted 80% and PBZ depleted 43% of the total mineralocorticoid receptors. elucidated whether the resultant complexes are functionally active as mineralocorticoids. To answer these questions we turned to physiological studies attempting to evaluate the mineralocorticoid potency of those NSAID possessing binding activity.
Of the drugs tested, PBZ and OBZ were the most potent inhibitors of [8H]aldosterone binding. In the physiological studies these drugs definitively demonstrated sodium-retaining activity. That this activity is receptor mediated is supported by the inhibition of the salt retention by spironolactone, a competitive inhibitor of mineralocorticoid-receptor binding (25, 26) . However, the relevance of these findings to the clinical setting remains an open issue. Consideration must be given to species variation and other factors to determine the role of this postulated mechanism in humans. Variation in the rate of metabolism of PBZ exists between species, the half-life in the rat being 3-6 h and in man about 72 h (27) . Thus the effects seen in the rat would probably be magnified in humans because of the much slower clearance rate.
Since the binding events being studied are competitive, the dosages selected have emphasized molar ratios of NSAID to physiological levels of steroids. Assuming aldosterone concentrations of 10 ng/100 ml and therapeutic concentrations of ASA --20 mg/100 ml (3), PBZ --10 mg/100 ml (7, 27) , and IDM-0.1 mg/100 ml (28, 29) (3, 7, 27) . Additionally, the results in the physiological experiments add further support to the hypothesis. The dosages utilized were not excessive, and the rats showed no ill effects despite the fact that they were more susceptible to stress because of their adrenalectomized status.
It is noteworthy that PBZ and OBZ exhibited roughly equivalent potency to aldosterone when administered at a molar ratio of 10,000: 1 in the physiological experiments, whereas in the binding studies, a 100,000: 1 ratio is required for equivalent competitive potency. In an attempt to explain this discrepancy, the depletion studies were performed employing the same doses used in the physiological experiments. In vivo, PBZ and aldosterone both appeared to achieve higher receptor occupancy rates (Table III) than in in vitro competition ( Fig. 1 ), but aldosterone remained relatively more potent at the time point examined. Although the explanation for the difference mentioned is not clear from the data available, it should be noted that PBZ has a significantly longer half-life in the rat then aldosterone, possibly allowing for a more prolonged effect in vivo. The relationship between binding affinity and functional potency is complex involving multiple variables including absorption, plasma binding, metabolic clearance rate, and other factors.
ASA and SS, although demonstrating some competitive potency in the binding studies, failed to elicit sodium retention. Previous workers have differed in their conclusions as to whether salt retention follows ASA administration (9) (10) (11) 30) . The absence of a clearcut biological response in the presence of binding suggests that the drug-receptor complexes formed are either suboptimally active or inactive (19, 26, 31) . In the absence of agonist potency, one would predict that the salicylates would function as competitive aldosterone antagonists. This possibility was not tested. ASA is not usually associated with alterations in salt metabolism as a side effect, however several reports in man and experimental animals have indicated that modest doses of ASA inhibit the diuretic action of spironolactone (11, 14, 15) . Because of the low affinity demonstrated for the mineralocorticoid receptors by ASA, it is unlikely that inhibition of spironolactone diuresis is due to mineralocortocoid enhancement by an additional weak agonist. Rather, it seems that other mechanisms are involved, possibly the induction by ASA of an increase in the metabolic clearance rate of spironolactone.
It is well known that PBZ and OBZ commonly cause salt and water retention. It would seem that the mechanism described here is the basis for this side effect. It is of interest that both PBZ and OBZ are active in the binding system and the physiological system, suggesting that both drugs possess activity. This conclusion is supported by the in vivo studies where assays for PBZ indicated that the parent compound was still present in the blood at a time that significant competition had occurred. A metabolic product common to both drugs may be the active principal but, in accord with the binding data, it would have to be formed in vitro. IDM is also known to result in salt and water retention (3) (32) . Perhaps the greatest difficulty with this hypothesis is reconciling the structural differences between NSAID and steroids. Yet if we accept the thesis that some NSAID have intrinsic mineralocorticoid agonist activity, we must be cautious in eliminating a similar mechanism for glucocorticoid activity. Further studies on this point are presently being carried out.
The significance of the structural aspects of these results should be emphasized. We are postulating that nonsteroidal compounds (i.e. PBZ and OBZ) can achieve significant binding in what are considered to be highly specific steroidal binding sites. Precedent exists for this concept. The nonsteroid diethylstilbesterol has been found to manifest all of the properties of steroidal estrogens and has an even higher affinity for the estrogen receptor than estradiol-17,8 (33) . Additionally, flutamide, another nonsteroid, has been described as a competitive inhibitor of androgen binding to its receptor in ventral prostate (34) . The apparent generality of the concept that nonsteroids can bind to steroid receptors as both agonists or antagonists may have wide-spread implications for the future design of pharmacologically active agents.
